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Background
Despite various immunosuppressive agents, juvenile
idiopathic arthritis (JIA) related uveitis often take a ser-
ious course that leads to sight threatening
complications.
Aim
To evaluate efficacy of Abatacept in combined treatment
of JIA related uveitis.
Methods
10 children aged 4 – 12 years with anterior uveitis asso-
ciated with JIA were treated by Abatacept in standard
infusions pattern and doses. Indication for using Abata-
ceptwas ineffectiveness of standard therapy of arthritis
and/or uveitis. 6 patients were suffering from polyarticu-
lar variants, 4 – oligoarticular JIA. Abatacept was com-
bined with Methotrexate in 9, Sulfasalazin in 1 and low-
dose steroids in 4 children. 3p a t i e n t sw e r es w i t c h e dt o
Abatacept from Infliximab due to non-efficacy, 7
received abatacept as a first line biologic. 9 patients had
bilateral eye involvement. At the administration of Aba-
tacept severe inflammation was seen in 1, moderate in
7, mild in 2 of the cases. Follow up period ranged from
3 to 11 month (mean 7.6). The main outcome measure
was the degree of inflammation.
Results
Remission of uveitis in current treatment was achieved
in 6 (60%), improvement in the degree of inflammation
in 2 (20%) of the cases. The initial response was seen
after the 2
nd – 4
th injection. From patients switched
from Infliximab to Abatacept 1 achieved remission of
uveitis, 1 improved, 1 remained stable. Patients with
remission of uveitis diminished or discontinued topical
medications. No ocular or systemic adverse effects were
observed. Glaucoma or cataract surgery was uncompli-
cated in all 4 cases.
Conclusions
Administration of Abatacept was effective in 80% of
children with JIA related uveitis. Further investigations
are required to define clear indications for this treat-
ment in severe uveitis.
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